Could a simple antibiotic cocktail slash infection risk in colon cancer surgery?
NCT ID NCT07429760
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of preparing the bowel before left-sided colorectal cancer surgery: standard mechanical bowel prep alone versus mechanical prep plus oral antibiotics (rifaximin and metronidazole). The goal is to see if adding antibiotics reduces surgical site infections within 30 days. Sixty adults scheduled for curative surgery are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Rifampicin (also called Metronidazole) and Rifaximin
- What this could lead to
- If it works, this could show that adding oral antibiotics to standard bowel prep lowers the risk of surgical site infections after colorectal cancer surgery.
- What could go wrong
- This is a small, early-stage trial with only 60 participants, so results may not apply to all patients. The antibiotics may cause side effects or not reduce infections as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients * Diagnosed cases of left sided (distal to splenic flexure) colorectal cancer undergoing elective curative sphincter preserving surgery. * No contraindication for preoperative administration of oral antibiotics and mechanical bowel preparation. Exclusion Criteria: Emergency surgery * Palliative surgery * Unwilling to participate in a trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shaukat Khanam Memorial Cancer Hospital & Research Centre Lahore
Lahore, Punjab Province, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab test tell which chemo works for colon cancer?
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days